Sanofi’s Cablivi cleared for rare bleeding disorder
Patients with the rare clotting disorder acquired thrombotic thrombocytopenic purpura (aTTP) have gained a new treatment option in Europe with the approval of Sanofi’s Cablivi.
Read More
Tag: Ablynx
Ablynx’ vobarilizumab fails in lupus trial
Ablynx’ vobarilizumab has failed to hit targets in a mid-stage trial assessing its safety and effectiveness as a treatment for systemic lupus erythematosus (SLE).
Read More
Sanofi snaps up Ablynx for 3.9bn euros
Sanofi has announced its intention to buy Belgian drugmaker Ablynx via a deal valued at around 3.9 billion Euros, beating Novo Nordisk to the finish line.
Read More
Novo makes second move on Ablynx
Novo Nordisk is switching up a gear its efforts to acquire Belgian biopharma Ablynx, with a heightened offer valued at around 2.6 billion euros.
Read More
Sanofi, Ablynx sign $2.7bn research, licensing pact
Sanofi has signed a research pact and licensing deal with Ablynx that could bring as much as $2.7 billion euros to the Belgian biotech’s coffers if all targets are met.
Read More
Ablynx files caplacizumab for ultra rare blood disorder
Patients in Europe with the ultra rare blood clotting disorder acquired thrombotic thrombocytopenic purpura (aTTP) are a step closer to getting the first therapeutic specifically indicated for treating the disease, after Ablynx filed for approval of caplacizumab.
Read More
- Ipsen announces new data on Dysport in neurological disease
- PMGroup Worldwide Ltd welcomes MAD World Summit
- Argenx receives review from FDA for VYVGART in seronegative gMG
- Nuclera extends Series C funding to advance antibody engineering
- Cellistic launches new iPSC-based platforms to expand immuno-oncology therapies
